Exscientia

Exscientia has the potential to be a star collaborator and a profitable drug developer
Exscientia has the potential to be a star collaborator and a profitable drug developer
Motley Fool
Exscientia
drug discovery
artificial intelligence
Flag link:
AI drug hunter Exscientia chops down 'rapidly emerging pipeline' to focus on 2 main oncology programs
AI drug hunter Exscientia chops down 'rapidly emerging pipeline' to focus on 2 main oncology programs
Fierce Biotech
Exscientia
artificial intelligence
drug development
Flag link:
Merck KGaA doubles up on AI partners, tapping BenevolentAI and Exscientia for drug discovery push
Merck KGaA doubles up on AI partners, tapping BenevolentAI and Exscientia for drug discovery push
Fierce Biotech
Merck KGaA
drug discovery
artificial intelligence
BenevolentAI
Exscientia
Flag link:
Exscientia builds cancer pipeline with two BMS drugs
Exscientia builds cancer pipeline with two BMS drugs
Pharmaphorum
Exscientia
Bristol Myers Squibb
oncology
EXS73565
EXS74539
Flag link:
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia
Fierce Biotech
Sanofi
R&D
artificial intelligence
Exscientia
Flag link:
Trio of Biopharmas Generates Over $500 Million for AI, Oncology Innovation
Trio of Biopharmas Generates Over $500 Million for AI, Oncology Innovation
BioSpace
funding
artificial intelligence
oncology
TrialSpark
CBMG Holdings
Exscientia
Flag link:
The cash won't stop for Exscientia as it makes a $300M+ Nasdaq debut
The cash won't stop for Exscientia as it makes a $300M+ Nasdaq debut
Endpoints
Exscientia
IPOs
artificial intelligence
Flag link:
Five Life Sciences Companies Ramping up the Fall Flood of IPOs
Five Life Sciences Companies Ramping up the Fall Flood of IPOs
BioSpace
IPOs
Exscientia
Sumitomo Dainippon Pharma
Cingluate
Tyra Biosciences
Procept BioRobotics
Flag link:
Gates Foundation backs COVID R&D at AI firm Exscientia
Gates Foundation backs COVID R&D at AI firm Exscientia
Pharmaforum
Gates Foundation
Exscientia
R&D
COVID-19
artificial intelligence
Flag link:
UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing
UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing
Pharmaforum
UK
biotech
Centessa
Achilles Therapeutics
Vaccitech
Exscientia
Oxford Nanopore
Gyroscope Therapeutics
Flag link:
Exscientia buys Allcyte to add patient sample testing to its AI platform
Exscientia buys Allcyte to add patient sample testing to its AI platform
Pharmforum
Exscientia
Allcyte
M&A
artificial intelligence
Flag link:
Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
Endpoints
Bristol Myers Squibb
Exscientia
R&D
Celgene
M&A
artificial intelligence
Flag link:
Exscientia starts trials of first AI-derived cancer immunotherapy
Exscientia starts trials of first AI-derived cancer immunotherapy
Pharmaforum
Exscientia
cancer immunotherapy
artificial intelligence
Flag link:
After years of partnerships, AI biotech Exscientia lands first major financing round at $60M
After years of partnerships, AI biotech Exscientia lands first major financing round at $60M
Endpoints
artificial intelligence
Exscientia
Novo Holdings
Flag link:
For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials
For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials
Forbes
artificial intelligence
OCD
drug development
DSP-1181
Sumitomo Dainippon
Exscientia
Flag link:
GSK adds to COPD pipeline as Exscientia deal bears fruit
GSK adds to COPD pipeline as Exscientia deal bears fruit
Pharmaforum
GSK
COPD
Exscientia
artificial intelligence
R&D
Flag link:
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Fierce Biotech
Celgene
Exscientia
artificial intelligence
oncology
autoimmune disease
drug discovery
Flag link:
EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts
EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts
Fierce Biotech
Europe
biotech
Brexit
BioNTech
GSK
artificial intelligence
Sanofi
Exscientia
Silence Therapeutics
RNAi
Flag link:
Sanofi inks €250M bispecific small molecule diabetes deal
Sanofi inks €250M bispecific small molecule diabetes deal
Fierce Biotech
Sanofi
small molecule drugs
diabetes
Exscientia
Flag link: